Block listing Return

RNS Number : 1986A

C4X Discovery Holdings PLC

01 February 2022

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Block Listing Return

1 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listing (excluding the additional block listing applications above and those block listings that have now been cancelled):

Name of applicant:		C4X Discovery Holdings plc
Name of scheme:		Warrants
Period of return:	From:	1 July 2021	To:	31 January 2022
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		106,964,288 ordinary shares of £0.01 each in the Company admitted to trading on 6 July 2021
Balance of unallotted securities under scheme(s) from previous return:		106,964,288 ordinary shares
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:   Number of securities issued/allotted under scheme(s) during period:		2,200,000
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		104,764,288

Name of contact:	Brad Hoy
Telephone number of contact:	[phone]

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

 

END

 

 

BLRSDIFIFEESEDF